Taeun Kang: Beyond Traditional ‘Blood Thinners’ – Cardiovascular and Thrombosis Therapeutics
Taeun Kang, Founder and Chief Growth Officer of Manhattan Signal, shared a post on LinkedIn:
“Pause and Note – Cardiovascular and Thrombosis Therapeutics
As shared previously, I have been spending more time independently researching cardiovascular therapeutics, thrombosis prevention, and emerging RNA-based medicines simply out of personal interest and curiosity around where the biotech and pharmaceutical industries may be heading.
Based on my research, below is a high-level market snapshot that I thought some people in biotech/pharma – and especially families impacted by cardiovascular conditions – may also find interesting.
It appears that the landscape is evolving beyond traditional ‘blood thinners’ into much more targeted next-generation cardiovascular approaches.
Current leaders still include major anticoagulants and antiplatelet therapies such as:
- Eliquis
- Xarelto
- Pradaxa
- Plavix
- Brilinta
At the same time, increasing attention appears to be shifting toward:
- Lp(a)-lowering therapies
- FXIa inhibitors
- RNA-based cardiovascular medicines
- Precision thrombosis prevention
Particularly interesting is the growing focus around Lipoprotein(a) [Lp(a)], which continues drawing attention in cardiovascular risk and thrombosis research.
Some major programs currently being watched across the industry include:
- Pelacarsen – Novartis
- Olpasiran – Amgen
- Zerlasiran – Silence Therapeutics
- Lepodisiran – Eli Lilly
I also found it fascinating how multiple modalities are emerging simultaneously, including:
- siRNA
- Antisense oligonucleotides (ASO)
- FXIa inhibition pathways
The intersection of RNA therapeutics, cardiovascular medicine, and preventative care may become one of the more important biotech themes of the next decade.
Question: How can we speed up these new emerging therapies?
To be continued”
Stay updated with Hemostasis Today.
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?
-
Jun 26, 2026, 18:27Pradip Pawar: Cell and Gene Therapy – Transforming Medicine in the 21st Century
-
Jun 26, 2026, 18:26Aviva Schwartz: How Can We Better Protect Patients After an Ischemic Stroke?
-
Jun 26, 2026, 18:25Does Reversing Factor Xa Inhibitors Really Carry as Much Thrombotic Risk as We Think? – RPTH Journal
-
Jun 26, 2026, 18:25Akshat Jain: Novel Therapies in Childhood Blood and Cancer Disorders
-
Jun 26, 2026, 16:57Abdul Muqtadir Abbasi: Anticoagulation in DVT Patients With Hidden Varices Requires Extreme Caution
-
Jun 26, 2026, 16:42Anesa Mulabecirovic: Why Von Willebrand Disease Takes Years to Diagnose in Women
-
Jun 26, 2026, 16:32Kaitlin Lichty: A New Identity Reflecting a Shared Legacy of Bleeding Disorders
-
Jun 26, 2026, 16:07Toong Youttananukorn: The WFH Registry Driving Better Care and Advocacy